OCS HealthcareBeta data

Oculis Holding AG

$7.63-1.04%

Price as of close on Nov 3, 2026 · Financials updated Oct 1, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: Switzerland
Market cap: 423.7M USD
Enterprise value: 153.2M USD
Full-time employees: 60

Overall health

Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Not enough data: growth

Would rank #733 of 1,157 fully scored healthcare companies (bottom 37%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on operating cash profit (EBITDA).Cheaper than 50% of peers on free cash flow, but only 0% on operating cash profit.
Relative to its free cash flow, Oculis looks cheaper than 50% of peers; relative to its operating cash profit (EBITDA), cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.Relative to its free cash flow, Oculis looks cheaper than 50% of peers; relative to its operating cash profit, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Financials may be out of date. Latest financial period ended 10 months ago.
The latest financial period we have ended 10 months ago, so the scores may not reflect recent results.
Steadier share price. Beta 0.23: tends to move less than the market.
Oculis's shares have swung less with the market than most peers' (beta 0.23, below the market's 1.0).

StockQuotient Score

45/ 100

Oct 5 45 → Nov 4 45

Fundamentals: Yahoo Finance, not primary filings

Valuation

Is the price right?

30/100

Weak

2/3 inputs reported · Partial data

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yieldUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0148 · MAD: 0.0148

EBITDA yield-67.2%

Yahoo Finance · trailing 12 months · CHF→USD convertedNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-18.6%

Yahoo Finance · trailing 12 months · CHF→USD converted · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield55.4%

Yahoo FinanceReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

Insufficient data

Insufficient data: 0 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Profitability

Does it earn well?

15/100

Weak

2/3 inputs reported · Partial data

Since last quarter: No major change

Why

Weaker than most peers on:

▼ ROA
▼ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating marginUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0706 · MAD: 0.1217

Return on assets-41.9%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported value33% base weight · Z-score -8.13Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-56.2%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported value33% base weight · Z-score -6.07Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin0.0%

Yahoo Finance · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-43.7%

Yahoo Finance · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Stronger than most peers on:

▲ Debt / equity
▲ Beta
▲ Current ratio

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.23

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score 1.16Sector median: 0.6250 · MAD: 0.3380

Current ratio8.35×

Yahoo FinanceReported value33% base weight · Z-score 4.16Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.01×

Yahoo FinanceReported value33% base weight · Z-score 1.03Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Oculis

Is Oculis getting weaker?: Its latest SEC filing (Mar 4, 2026) showed no major changes. Its overall score is unchanged at 45/100 since Oct 28, 2026.
How is Oculis valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 30/100 against 1,393 healthcare peers. EBITDA yield -67.2% vs a peer median of 4.0% (weaker than 100% of peers).EBITDA yield -67.2% vs peers 4.0% (weaker than 100% of peers).
Is Oculis growing?: Insufficient data: 0 of 3 inputs reported (at least 2 needed).
How profitable is Oculis?: Less profitable than most of its peers. Profitability scores 15/100 against 1,393 healthcare peers. Return on assets -41.9% vs a peer median of 1.7% (weaker than 91% of peers).Return on assets -41.9% vs peers 1.7% (weaker than 91% of peers).
How risky is Oculis?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 0.01× vs a peer median of 0.22× (stronger than 88% of peers).Debt / equity 0.01× vs peers 0.22× (stronger than 88% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Dec 31, 2025 · filed Mar 4, 2026 · compared with the quarter ended Jun 30, 2025

No major changes

Worth watching: Oculis is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.

	Previous quarter	Latest quarter	Change
Net income (12 months)	−107.4M CHF	−99.0M CHF	−7.9%
Free cash flow (12 months)	−56.6M CHF	−66.6M CHF	+17.7%
Cash	64.3M CHF	81.3M CHF	+26.6%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Financials

Fiscal years from SEC annual filings · change vs the prior year · amounts in CHF, as reported

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Return on assets (ROA)	-32.0%	-104.4%	-77.7%	-71.3%	-41.9%	▲ 29 pts
Return on equity (ROE)	—	—	-94.7%	-116.9%	-50.5%	▲ 66 pts
Current ratio	11.81×	1.97×	5.29×	2.37×	5.96×	▲ 151%
Interest coverage	-176.43×	-599.56×	-61.38×	-114.56×	-98.05×	▲ 14%

OCS price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Not enough data: growth

Would rank #733 of 1,157 fully scored healthcare companies (bottom 37%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on operating cash profit (EBITDA).Cheaper than 50% of peers on free cash flow, but only 0% on operating cash profit.

Relative to its free cash flow, Oculis looks cheaper than 50% of peers; relative to its operating cash profit (EBITDA), cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.Relative to its free cash flow, Oculis looks cheaper than 50% of peers; relative to its operating cash profit, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Financials may be out of date. Latest financial period ended 10 months ago.

The latest financial period we have ended 10 months ago, so the scores may not reflect recent results.

Steadier share price. Beta 0.23: tends to move less than the market.

Oculis's shares have swung less with the market than most peers' (beta 0.23, below the market's 1.0).

Questions investors ask about Oculis

Is Oculis getting weaker?

Its latest SEC filing (Mar 4, 2026) showed no major changes. Its overall score is unchanged at 45/100 since Oct 28, 2026.

How is Oculis valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 30/100 against 1,393 healthcare peers. EBITDA yield -67.2% vs a peer median of 4.0% (weaker than 100% of peers).EBITDA yield -67.2% vs peers 4.0% (weaker than 100% of peers).

Is Oculis growing?

Insufficient data: 0 of 3 inputs reported (at least 2 needed).

How profitable is Oculis?

Less profitable than most of its peers. Profitability scores 15/100 against 1,393 healthcare peers. Return on assets -41.9% vs a peer median of 1.7% (weaker than 91% of peers).Return on assets -41.9% vs peers 1.7% (weaker than 91% of peers).

How risky is Oculis?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 0.01× vs a peer median of 0.22× (stronger than 88% of peers).Debt / equity 0.01× vs peers 0.22× (stronger than 88% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Net income (12 months)

−107.4M CHF

−99.0M CHF

−7.9%

Free cash flow (12 months)

−56.6M CHF

−66.6M CHF

+17.7%

Cash

64.3M CHF

81.3M CHF

+26.6%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Return on assets (ROA)

-32.0%

-104.4%

-77.7%

-71.3%

-41.9%

▲ 29 pts

Return on equity (ROE)

—

-94.7%

-116.9%

-50.5%

▲ 66 pts

Current ratio

11.81×

1.97×

5.29×

2.37×

5.96×

▲ 151%

Interest coverage

-176.43×

-599.56×

-61.38×

-114.56×

-98.05×

▲ 14%